Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell Lymphoma

The study evaluated the efficacy of VDC-1101 in 12 dogs with cutaneous T-cell lymphoma (CTCL). The treatment involved a 30-minute IV infusion every 21 days, alongside prednisone. Among 11 evaluable dogs, the objective response rate (ORR) was 45%, with 1 complete response (CR), 4 partial responses (PR), 2 stable disease (SD), and 4 progressive disease (PD). The median progression-free survival (PFS) was 37.5 days, with one dog maintaining a CR for over a year. Adverse events were mild, with gastrointestinal and hematologic issues being the most common. The study concluded that VDC-1101 showed activity against canine CTCL and could be a potential treatment option for this disease.